Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00089440
First received: August 5, 2004
Last updated: October 25, 2007
Last verified: July 2005
  Purpose

The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.


Condition Intervention Phase
Amphetamine-Related Disorders
Drug: Aripiprazole
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Assessment of Interactions Between IV Methamphetamine and Aripiprazole

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Adverse effect measures
  • pharmacokinetic assessment

Estimated Enrollment: 17
Study Start Date: June 2004
Estimated Study Completion Date: March 2005
Detailed Description:

This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking.
  • Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.

Exclusion Criteria:

  • Please contact the site for more information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00089440

Locations
United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
United States, New York
New York University, School of Medicine
New York, New York, United States, 10016
Sponsors and Collaborators
Investigators
Principal Investigator: Thomas Newton, M.D. University of California, Los Angeles
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00089440     History of Changes
Other Study ID Numbers: NIDA-MDS-0002-1
Study First Received: August 5, 2004
Last Updated: October 25, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Amphetamine-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders
Aripiprazole
Methamphetamine
Adrenergic Agents
Adrenergic Uptake Inhibitors
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Central Nervous System Stimulants
Dopamine Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sympathomimetics
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on November 19, 2014